Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Response Delay Clear all
Completed Phase 1Phase 2 Interventional Results available

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

NCT00923351
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 22, 2026, 4:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Disseminating Effective Habits for Long-Term Weight Loss

NCT00709501
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Disseminating Effective Habits for Long-term Weight Loss, Achieve Together website
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 22, 2026, 4:35 PM EDT
Recruiting Phase 2 Interventional

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

NCT06376526
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Biological
Lead sponsor
Dickran Kazandjian, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

NCT02240108
View directory record Official record
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
78
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Wellness Recovery Action Planning

NCT01024569
View directory record Official record
Conditions
Mental Disorders
Interventions
Wellness Recovery Action Planning (WRAP)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Substitution Heuristic on Proportional Tasks

NCT06762366
View directory record Official record
Conditions
Proportional Reasoning, Substitution Heuristic
Interventions
Additional Incentive, Response Delay, Baseline Performance
Behavioral
Lead sponsor
Michelle Hurst, PhD
Other
Eligibility
18 Years to 64 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

NCT01578551
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Metformin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Results available

Family Connections: Cultural Adaptation and Feasibility Testing for Rural Latino Communities

NCT04731506
View directory record Official record
Conditions
Childhood Obesity
Interventions
Family Connections
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
6 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional

Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia

NCT00380731
View directory record Official record
Conditions
Social Phobia
Interventions
Individual Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tracking Intervention Effects With Eye Tracking

NCT02856061
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pivotal Response Treatment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 7 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 22, 2026, 4:35 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Health Adaptation & Resilience Mobilization (CHARM) HeatWise

NCT07500545
View directory record Official record
Conditions
Heat Illness
Interventions
CHARM HeatWise
Behavioral
Lead sponsor
Public Health Institute, California
Other
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakeport, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 4:35 PM EDT
Completed No phase listed Observational

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

NCT00238459
View directory record Official record
Conditions
HIV Infections
Interventions
Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dry Needling in Subjects With Delayed Onset Muscle Soreness

NCT03876080
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Dry needling, Sham needling
Other
Lead sponsor
Bradley University
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Intervention for First Year College Students

NCT03750838
View directory record Official record
Conditions
Underage Alcohol Use
Interventions
Text Messaging Intervention
Behavioral
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 19 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Phase 1 Interventional

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

NCT01649258
View directory record Official record
Conditions
Breast Cancer, Nausea, Vomiting
Interventions
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Testing of the Alert for Atrial Fibrillation Program

NCT01988974
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Alert for Atrial Fibrillation Program, Healthy Sleep
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 22, 2026, 4:35 PM EDT
Recruiting Early Phase 1 Interventional

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

NCT03594630
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Chemotherapy, Patient Observation, Questionnaire Administration, Resection of Rectum
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Results available

A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis

NCT01625923
View directory record Official record
Conditions
Idiopathic Gastroparesis
Interventions
Olanzapine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

NCT02019524
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 22, 2026, 4:35 PM EDT
Withdrawn Not applicable Interventional

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

NCT00551265
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab
Drug · Procedure · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 22, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

NCT01379274
View directory record Official record
Conditions
MDS
Interventions
Lenalidomide and azacitidine combination
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 22, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Muscle Delay Characterization

NCT04094571
View directory record Official record
Conditions
Neurological Disorders
Interventions
Functional Electrical Stimulation (FES) Control Protocol, Functional Electrical Stimulation (FES) Angle Protocol
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 22, 2026, 4:35 PM EDT